Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation

Vergis, Roy, Corbishley, Catherine M, Thomas, Karen, Horwich, Alan, Huddart, Robert, Khoo, Vincent, Eeles, Ros, Sydes, Matthew R, Cooper, Colin S ORCID: https://orcid.org/0000-0003-2013-8042, Dearnaley, David and Parker, Chris (2010) Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. International Journal of Radiation Oncology, Biology, Physics, 78 (1). pp. 35-41. ISSN 1879-355X

Full text not available from this repository. (Request a copy)

Abstract

Established prognostic factors in localized prostate cancer explain only a moderate proportion of variation in outcome. We analyzed tumor expression of apoptotic markers with respect to outcome in men with localized prostate cancer in two randomized controlled trials of radiotherapy dose escalation.

Item Type:	Article
Additional Information:	Copyright (c) 2010 Elsevier Inc. All rights reserved.
Uncontrolled Keywords:	aged,aged, 80 and over,analysis of variance,androgen antagonists,follow-up studies,humans,male,middle aged,neoadjuvant therapy,neoplasm proteins,neoplasm staging,prostate-specific antigen,prostatic neoplasms,proto-oncogene proteins c-bcl-2,proto-oncogene proteins c-mdm2,radiotherapy dosage,tissue array analysis,tumor suppressor protein p53,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Depositing User:	Pure Connector
Date Deposited:	20 Jan 2014 16:00
Last Modified:	24 Oct 2022 05:31
URI:	https://ueaeprints.uea.ac.uk/id/eprint/46136
DOI:	10.1016/j.ijrobp.2009.07.1728

Actions (login required)

View Item